 |
Jean Wang, M.D., Ph.D.
|
|
Jean Wang, M.D., Ph.D. Assistant Professor of Medicine
Dr. Wang received her undergraduate and medical education at Brown University, graduating in 1998. She then continued her training at Johns Hopkins Hospital, where she completed her residency in Internal Medicine and fellowship in Gastroenterology. After completing her training, she was recruited to join the faculty at Johns Hopkins in 2004. While at Hopkins, she also completed a Ph.D. in Clinical Investigation through the Johns Hopkins School of Public Health.
Dr. Wang joined the Division of Gastroenterology at Washington University in 2009 and specializes in the evaluation and treatment of patients with gastroesophageal reflux disease and Barrett's esophagus. She is also interested in colon cancer screening and the prevention and control of other gastrointestinal cancers. She is currently conducting an NIH-funded clinical research study on patients with Barrett's esophagus to determine biomarkers that predict the risk of esophageal cancer in these patients. She also has interests in public health and outcomes research in gastrointestinal disorders.
Publications:
Wang J, Carson E, Lapane K, Eaton C, Gans K, Lasater T. The effect of physician office visits on CHD risk factor modification as part of a worksite cholesterol screening program. Preventive Medicine 1999; 28: 221-228.
Wang JS, Cromwell DM. Upper gastrointestinal bleed. In: Cheng A, Zaas A, eds. The Osler Medical Handbook. Philadelphia: 2003; Mosby.
Wang J and Donowitz M. Irritable bowel syndrome. In: Peipert J and Leppert P, ed. Primary Care for Women. Philadelphia: 2004; Lippincott Williams & Wilkins.
Powell E, Leoni LM, Canto MI, Forastiere AA, Iacobuzio-Donahue CA, Wang JS, Maitra A, Montgomery E. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal non-invasive precursor lesions and therapeutic implications. Am J Surg Pathol 2005; 29:1497-1504.
Sui G, Zhou S, Wang J, Canto M, Lee EE, Eshleman JR, Montgomery EA, Sidransky D, Califano JA, Maitra A. Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: a biomarker for the early detection of cancer. Molecular Cancer 2006, 5:73 (13 December 2006).
Daniels JA, Gibson MK, Xu L, Sun S, Canto MI, Heath E, Wang J, Brock M, Montgomery E. Gastrointestinal tract epithelial changes associated with taxanes: marker of drug toxicity versus effect. Am J Surg Pathol 2008; 32(3):473-7.
Sato F, Jin Z, Schulmann K, Wang J, Ito T, Kan T, Hamilton JP, Yang J, Paun B, David S, Olaru A, Cheng Y, Mori Y, Abraham JM, Fredericksen M, Wang KK, Canto M, Romero Y, Feng Z, Meltzer SJ. Three-tiered risk stratification method to predict neoplastic progression in Barrett’s esophagus using epigenetic and clinical features. PLoS ONE. 2008 Apr 2;3(4):e1890.
Alvarez H, Young KT, Roy I, Xu G, Prasad PN, Wang J, Canto M, Eshleman JR, Montgomery E, Maitra A. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model. Nanomedicine 2008 Dec;4(4):295-301.
Wang JS and Awad MM. Gastroenterology section. In: Kahan S and Miller R, ed. In a Page Signs and Symptoms, second edition. Philadelphia: 2008; Lippincott Williams & Wilkins.
Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, Olaru AV, Paun BC, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM, Agarwal R, David S, Abraham JM, Wolfsen HC, Wallace MB, Shaheen NJ, Washington K, Wang J, Canto MI, Bhattacharyya A, Nelson MA, Wagner PD, Romero Y, Wang KK, Feng Z, Sampliner RE, Meltzer SJ. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res. 2009; 69(10): 4112-4115.
Wang JS, Guo MZ, Montgomery EA, Herman JG, Canto MI. p16 and APC DNA promoter hypermethylation predicts progression to cancer in Barrett’s esophagus. Am J of Gastro 2009; 104(9):2153-60.
Division of Gastroenterology
|
